Image Sourced ShutterStock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Elixinol Global subsidiary Nunyara Pharma has been granted a license to manufacture medical cannabis
  • Nunyara can manufacture cannabis tinctures, extracts and cannabis resin
  • The company is currently waiting for its approval to receive its Medicinal Cannabis Licence

Elixinol Global subsidiary Nunyara Pharma has been granted a license to manufacture medical cannabis.

The Australian Office of Drug Control gave the license to Nunyara to manufacture cannabis tinctures, extracts and cannabis resin.

Cannabis Tinctures is also known as green or golden dragon and are alcohol based cannabis extracts, essentially infused alcohol.

A Cannabis extract is an oil-like substance that comes from the plant.

Cannabis Resin is a dark to light brown substance which is scraped off the surface of the Cannabis Plant and pressed into a solid lump.

Elixinol Global is a global leader in the cannabis industry, selling hemp-derived CBD dietary supplements, hemp food and wellness products, as well as the farming and manufacture of medicinal cannabis products.

Nunyara founded in 2014 to participate in the emerging Australian medicinal cannabis market.

The company is currently waiting for its approval to receive its Medicinal Cannabis Licence which will allow the Company to farm and produce cannabis for medicinal purposes.

Elixinol CEO, Stratos Karousos is pleased with the approval.

“The granting of the Manufacture Licence is extremely exciting and we look forward to also being granted our Medicinal Cannabis Licence shortly which will complete our licence application process for Nunyara,” he said.

EXL by the numbers
More From The Market Herald

" Oceania Healthcare (ASX:OCA) announces $500m sustainability-linked loan

Oceania Healthcare (ASX:OCA) has implemented its $500 million five-year sustainability-linked loan (SLL) to support its commitment…
Nyrada (ASX:NYR) - CEO, James Bonnar

" Nyrada (ASX:NYR) announces start date for cholesterol lowering program

Nyrada (ASX:NYR) announces its first-in-human study for cholesterol lowering is expected to begin during the first…
The Market Herald Video

" Chimeric Therapeutics (ASX:CHM) expands license agreement with University of Pennsylvania

Chimeric Therapeutics (ASX:CHM) expands a license agreement for its antigen receptor therapies with the University of…

" Creso Pharma’s (ASX:CPH) Mernova receives A$12k purchase order

Creso Pharma's (ASX:CPH) wholly-owned Canadian subsidiary Mernova Medicinal has received a maiden order for its Ritual…